Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors.

The excess risk of second malignancy after Hodgkin disease is an increasing problem. In light of the long-term data, guidelines for follow-up of survivors of Hodgkin disease need to be redefined. In this study we attempt to analyze the long-term risks and temporal trends, identify patient- and treatment-related risk factors, and determine the prognosis of patients who develop a second malignancy after radiation treatment with or without chemotherapy for Hodgkin disease. Among 1319 patients with clinical stage I-IV Hodgkin disease, 181 second malignancies and 18 third malignancies were observed. With a median follow-up of 12 years, the relative risk (RR) and absolute excess risk of second malignancy were 4.6 and 89.3/10 000 person-years. The RR was significantly higher with combined chemotherapy and radiation therapy (6.1) than with radiation therapy alone (4.0, P =.015). The risk increased with increasing radiation field size (P =.03) in patients who received combined modality therapy, and with time after Hodgkin disease. After 15 and 20 years, there was a 2.3% and 4.0% excess risk of second malignancy per person per year. The 5-year survival after development of a second malignancy was 38.1%, with the worst prognosis seen after acute leukemia and lung cancer. The excess risk of second malignancy after Hodgkin disease continues to be increased after 15 to 20 years, and there does not appear to be a plateau. Our analysis suggests that the risk may be reduced with smaller radiation fields, as are used in current trials of abbreviated chemotherapy and limited-field radiation therapy.

[1]  C. Borel,et al.  Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  C Boetes,et al.  MR imaging in screening women at increased risk for breast cancer. , 2001, Magnetic resonance imaging clinics of North America.

[3]  G. Masala,et al.  The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hospital. , 2001, International journal of radiation oncology, biology, physics.

[4]  M. Williams,et al.  Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Yasuda,et al.  Application of positron emission tomography imaging to cancer screening , 2000, British Journal of Cancer.

[6]  T. Powles,et al.  Chemoprevention options for BRCA1 and BRCA2 mutation carriers. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Warren,et al.  Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study , 2000 .

[8]  B. Aleman,et al.  [Second primary tumors in patients treated at an early age for Hodgkin's disease; consequences for the follow-up]. , 2000, Nederlands tijdschrift voor geneeskunde.

[9]  D. Aeppli,et al.  The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. , 2000, International journal of radiation oncology, biology, physics.

[10]  S. Jeffrey,et al.  Management of breast cancer after Hodgkin's disease. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Lister,et al.  Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Hagenbeek,et al.  Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S F Keevil,et al.  Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. , 2000, Magnetic resonance imaging.

[14]  A. Hagenbeek,et al.  Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations. , 2000, International journal of radiation biology.

[15]  W. Wilmanns,et al.  Second malignancies after Hodgkin's disease: the Munich experience , 1999, Annals of Hematology.

[16]  S. Hancock,et al.  The Janeway lecture. Hodgkin's disease--finding the balance between cure and late effects. , 1999, The cancer journal from Scientific American.

[17]  D. Neuberg,et al.  Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[19]  F. Mandelli,et al.  The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. , 1998, Haematologica.

[20]  C. Gisselbrecht,et al.  Results of three courses of adriamycin, bleomycin, vindesine, and dacarbazine with subtotal nodal irradiation in 189 patients with nodal Hodgkin's disease (stage I, II and IIIA). , 1997, Hematology and cell therapy.

[21]  C. Willett,et al.  High risk of breast carcinoma after irradiation of young women with Hodgkin's disease , 1997, Cancer.

[22]  J. Bogart,et al.  Increased risk of breast cancer in splenectomized patients undergoing radiation therapy for Hodgkin's disease. , 1997, International journal of radiation oncology, biology, physics.

[23]  F. Mandelli,et al.  Analysis of the risk of solid tumor following Hodgkin's disease. , 1997, Haematologica.

[24]  D. Zelterman,et al.  Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Kalish,et al.  Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. , 1996, Blood.

[26]  A. Hagenbeek,et al.  Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. , 1995, Journal of the National Cancer Institute.

[27]  L. Prosnitz,et al.  Second solid malignancies after combined modality therapy for Hodgkin's disease. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Zauber,et al.  Incidence of second cancers in patients treated for Hodgkin's disease. , 1995, Journal of the National Cancer Institute.

[29]  L. Kalish,et al.  Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. , 1995, The cancer journal from Scientific American.

[30]  W. D. Ray 4. Modelling Survival Data in Medical Research , 1995 .

[31]  B. Meunier,et al.  [Breast cancer after treatment of Hodgkin's disease]. , 1995, Journal de gynecologie, obstetrique et biologie de la reproduction.

[32]  David Collett Modelling Survival Data in Medical Research , 1994 .

[33]  J. Bosq,et al.  Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen? , 1994, Blood.

[34]  A. Hagenbeek,et al.  Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  V. Boddi,et al.  Second solid tumors and leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution. , 1994, International journal of radiation oncology, biology, physics.

[36]  S. Zimmerman,et al.  Hodgkin's disease: study of treatment intensities and incidences of second malignancies. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  N. Day,et al.  Lung cancer following Hodgkin′s disease: A case‐control study , 1992, International journal of cancer.

[38]  D. Dershaw,et al.  Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Henry-Amar Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  F. Zunino,et al.  A preoperative single course of high-dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II carcinoma of the cervix. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  P. Mazza,et al.  Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Cosset,et al.  Long-term toxicity of early stages of Hodgkin's disease therapy: The EORTC experience , 1991 .

[43]  M. Henry-Amar,et al.  Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease. , 1990, Seminars in oncology.

[44]  J. Fermanian,et al.  Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  N. Day,et al.  Leukemia following Hodgkin's disease. , 1990, The New England journal of medicine.

[46]  M. Deutsch Second Primary Tumors in Treated Patients , 1990 .

[47]  M. Tucker,et al.  Risk of second cancers after treatment for Hodgkin's disease. , 1988, The New England journal of medicine.

[48]  R. Gray A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[49]  H. Hansen,et al.  RISK OF THERAPY-RELATED LEUKAEMIA AND PRELEUKAEMIA AFTER HODGKIN'S DISEASE Relation to Age, Cumulative Dose of Alkylating Agents, and Time from Chemotherapy , 1987, The Lancet.

[50]  P. Duffey,et al.  Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. , 1987, The New England journal of medicine.

[51]  A. Santoro,et al.  Second acute leukemia and other malignancies following treatment for Hodgkin's disease. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  F. Greco,et al.  Lung cancer in Hodgkin's disease: association with previous radiotherapy. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Boivin,et al.  Second primary cancers following treatment of Hodgkin's disease. , 1984, Journal of the National Cancer Institute.

[54]  A. Aisenberg Acute nonlymphocytic leukemia after treatment for Hodgkin's disease. , 1983, The American journal of medicine.

[55]  Coltman Ca,et al.  Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year followup. , 1982 .

[56]  A. Santoro,et al.  Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease. , 1982, Blood.

[57]  E. Glatstein,et al.  Hematologic neoplasia in patients treated for Hodgkin's disease. , 1977, The New England journal of medicine.

[58]  J. Whang‐Peng,et al.  SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION , 1975, The Lancet.

[59]  V. Devita,et al.  Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. , 1972, The New England journal of medicine.

[60]  T. Szasz Bad habits are not diseases. A refutation of the claim that alcoholism is a disease. , 1972, The Lancet.

[61]  Cornish Cb,et al.  MEDICAL TREATMENT OF OSTEOARTHRITIS. , 1965, Lancet.